课题基金 / 基金详情

Threshold control for T cell antigen receptor

Threshold control for T cell antigen receptor
T细胞抗原受体的阈值控制
批准号:
6721417
负责人:
MAKIO IWASHIMA
金额:
$10.85万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-04-01 至 2006-03-31

项目摘要

项目成果

MAKIO IWASHIMA的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: (Adapted from Applicant's Abstract) My long-term career goal is to elucidate the mechanisms of how the immunological repertoire is formed. The recognition of antigen by T cells plays a critical role to determine the fate of each T cell clone and to ultimately establish the repertoire of the immune system. Thus, I have focused my research on the T cell antigen receptor (TCR)- derived signals that determine T cell fate. The immediate goal is to identify the mechanism that defines the two different types of T cell responses. Antigenic peptides (agonist) induce full activation of mature T cells to produce IL-2, to express surface proteins such as CD25 (IL-2 receptor alpha chain) and CD69, and to proliferate. In contrast, partial agonist peptides induce expression of the surface antigens but not other responses. The research proposed here will determine the signals exclusively involved in the agonistic activation of T cells. ZAP-70, a cytoplasmic protein tyrosine kinase (PTK), is an essential molecule for TCR signal transduction. Preliminary results show that an adapter molecule Shc is a substrate of ZAP-70. My laboratory established a mutant T cell line lacking expression of Shc. Studies of this cell line revealed that Shc is indispensable for IL-2 production by TCR stimulation, but is not required for expression of other genes. I hypothesize that the involvement of the Shc signaling pathway is a determining factor to provoke agonistic activation of T cells and that it is the absence of the Shc signaling pathway that differentiates the full T cell response from the partial response. To test this, I will determine the mechanism whereby Shc functions to induce IL-2 gene expression and identify the biological effect of loss of Shc in mice. Completion of this study will provide information to understand the etiology of autoimmune diseases and immunodeficiencies. The K02 award will help the development of my career in three criteria; (1) Incorporation of rapidly developing genomic/proteomic technology into the analysis of T cell signaling pathway; (2) Extending and developing analytical methods on the signaling events at the single cell level; (3) Determining the significance of TCR signaling events in human immune disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Function of Siglec 5 in T cell activation.
  • 批准号:
    10373619
  • 项目类别:
  • 资助金额:
    $18.45万
  • 财政年份:
    2022
  • 负责人:
    MAKIO IWASHIMA
  • 依托单位:
Function of Siglec 5 in T cell activation.
  • 批准号:
    10665549
  • 项目类别:
  • 资助金额:
    $22.3万
  • 财政年份:
    2022
  • 负责人:
    MAKIO IWASHIMA
  • 依托单位:
Immune checkpoint modulation by bacterial metabolites.
  • 批准号:
    10246854
  • 项目类别:
  • 资助金额:
    $22.25万
  • 财政年份:
    2020
  • 负责人:
    MAKIO IWASHIMA
  • 依托单位:
Immunomodulatory properties of umbilical cord blood
  • 批准号:
    8606811
  • 项目类别:
  • 资助金额:
    $21.76万
  • 财政年份:
    2013
  • 负责人:
    MAKIO IWASHIMA
  • 依托单位:
海外基金